BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
수요일, 9월 30

Aldeyra Therapeutics Inc

ALDXNASDAQ
Trade with Public
Trade with Public
$1.23
-0.09-6.82%
가까이에: Sep 30, 5:00 PM EST
$1.26
0.032.44%
시간외: 4:38 PM EST
PRO
변동 이유?:Aldeyra Therapeutics shares are trading higher after the company announced ...
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

Aldeyra Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Aldeyra Therapeutics (ALDX).

Price Target Range — 8 Quarters

Analyst Consensus — 4 Analysts

3Buy
1Hold
Consensus RatingBuy# Analysts4Avg. Consensus PT$7Upside to Avg. PT+475.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →
DateFirmAnalystActionRating ChangePrice Target
Sep 30, 2026HC Wainwright & Co.Matthew CaufieldMaintainedNeutral$2
Sep 29, 2026BTIGThomas ShraderMaintainedBuy$9
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Neutral on Aldeyra Therapeutics, Maintains $2 Price Target

HC Wainwright & Co. analyst Matthew Caufield reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Neutral and maintains $2 price target.
Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Aldeyra Therapeutics, Maintains $9 Price Target

BTIG analyst Thomas Shrader reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Buy and maintains $9 price target.
Benzinga Newsdesk

This Trade Desk Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Analysts downgraded CF, ALDX, TTD, TME and DUOL. Check their ratings and price targets. Interested in TTD? See what analysts say.
Avi Kapoor

PRO
HC Wainwright & Co. Downgrades Aldeyra Therapeutics to Neutral, Lowers Price Target to $2

HC Wainwright & Co. analyst Matthew Caufield downgrades Aldeyra Therapeutics (NASDAQ:ALDX) from Buy to Neutral and lowers the price target from $10 to $2.
Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Aldeyra Therapeutics, Maintains $9 Price Target

BTIG analyst Thomas Shrader reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Buy and maintains $9 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Aldeyra Therapeutics, Maintains $10 Price Target

HC Wainwright & Co. analyst Matthew Caufield reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Buy and maintains $10 price target.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

BenzingaBenzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved